Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and tamoxifen in HR+/HER2- advanced breast cancer
NCT03423199Phase 3Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2018
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of palbociclib in Hormone-Receptor-Positive Breast Cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Feb 2018; status: active, not recruiting.
02
Drugs
palbociclib
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT03423199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03423199.